Cartesian Therapeutics, INC 8-K filings

Cartesian Therapeutics announced its first quarter 2024 financial results and provided a business update, emphasizing the progress of its mRNA cell therapy pipeline, particularly Descartes-08.

Cartesian Therapeutics has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for ten consecutive days.

Cartesian Therapeutics is progressing its mRNA cell therapy pipeline, with key clinical trial readouts and program initiations expected in the near term, supported by a strong cash position.

Cartesian Therapeutics has formalized employment agreements with its Chief Scientific Officer and Chief Technology Officer, outlining compensation and terms of employment.

Cartesian Therapeutics has received shareholder approval for the conversion of Series A preferred stock to common stock and a 1-for-30 reverse stock split.

Cartesian Therapeutics has received notice from Astellas of the termination of their license and development agreement for the Xork product, effective June 6, 2024.

Cartesian Therapeutics announced its full year 2023 financial results, provided a business update, and highlighted key milestones for its mRNA CAR-T cell therapy programs.

Cartesian Therapeutics has entered into a lease agreement for a new 20,000 square foot manufacturing and office space in Frederick, Maryland, to support its mRNA cell therapy development.

Cartesian Therapeutics, formerly Selecta Biosciences, has filed an amended 8-K report including financial statements and pro forma information following its merger with Cartesian Bio, LLC.

Cartesian Therapeutics has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, putting its listing at risk.